Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

被引:8
作者
Rosen, Jeffrey B. [1 ]
Ballantyne, Christie M. [2 ,3 ]
Hsueh, Willa A. [4 ]
Lin, Jianxin [5 ]
Shah, Arvind K. [5 ]
Lowe, Robert S. [5 ]
Tershakovec, Andrew M. [5 ]
机构
[1] Clin Res South Florida, Coral Gables, FL 33134 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA
[4] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
关键词
TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR RISK; HYPERCHOLESTEROLEMIA; EZETIMIBE; DYSLIPIDEMIA; COMBINATION; MANAGEMENT; SIMVASTATIN; PREVENTION; SUBCLASSES;
D O I
10.1186/s12944-015-0075-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin and atorvastatin treatment efficacy in patients with MetS. Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128 subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein (hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg). Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups. Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides, very-LDL-C, and hs-CRP results were more variable but similar between treatment groups. Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated.
引用
收藏
页数:12
相关论文
共 30 条
[1]   Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses [J].
Abate, Nicola ;
Catapano, Alberico L. ;
Ballantyne, Christie M. ;
Davidson, Michael H. ;
Polis, Adam ;
Smugar, Steven S. ;
Tershakovec, Andrew M. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (02) :91-105
[2]   Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity [J].
Alberti, K. G. M. M. ;
Eckel, Robert H. ;
Grundy, Scott M. ;
Zimmet, Paul Z. ;
Cleeman, James I. ;
Donato, Karen A. ;
Fruchart, Jean-Charles ;
James, W. Philip T. ;
Loria, Catherine M. ;
Smith, Sidney C., Jr. .
CIRCULATION, 2009, 120 (16) :1640-1645
[3]   Prevention and Rehabilitation - Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study [J].
Ballantyne, CM ;
Abate, N ;
Yuan, Z ;
King, TR ;
Palmisano, J .
AMERICAN HEART JOURNAL, 2005, 149 (03) :464-473
[4]   Ezetimibe plus simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study) [J].
Bardini, Gianluca ;
Giorda, Carlo B. ;
Pontiroli, Antonio E. ;
Le Grazie, Cristina ;
Rotella, Carlo M. .
CARDIOVASCULAR DIABETOLOGY, 2010, 9
[5]   Optimal management of lipids in diabetes and metabolic syndrome [J].
Brown, W. Virgil ;
Clark, Luther ;
Falko, James M. ;
Guyton, John R. ;
Rees, Tomas J. ;
Schonfeld, Gustav ;
Lopes-Virella, Maria F. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2008, 2 (05) :335-342
[6]   Lipoprotein management in patients with cardiometabolic risk [J].
Brunzell, John D. ;
Davidson, Michael ;
Furberg, Curt D. ;
Goldberg, Ronald B. ;
Howard, Barbara V. ;
Stein, James H. ;
Witztum, Joseph L. .
DIABETES CARE, 2008, 31 (04) :811-822
[7]   Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies [J].
Chan, Dick C. ;
Watts, Gerald F. .
EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (01) :13-30
[8]   Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither [J].
Conard, S. ;
Bays, H. ;
Leiter, L. A. ;
Bird, S. ;
Lin, J. ;
Hanson, M. E. ;
Shah, A. ;
Tershakovec, A. M. .
DIABETES OBESITY & METABOLISM, 2010, 12 (03) :210-218
[9]   The Metabolic Syndrome [J].
Cornier, Marc-Andre ;
Dabelea, Dana ;
Hernandez, Teri L. ;
Lindstrom, Rachel C. ;
Steig, Amy J. ;
Stob, Nicole R. ;
Van Pelt, Rachael E. ;
Wang, Hong ;
Eckel, Robert H. .
ENDOCRINE REVIEWS, 2008, 29 (07) :777-822
[10]  
Denke Margo, 2006, Diab Vasc Dis Res, V3, P93, DOI 10.3132/dvdr.2006.020